Nasdaq - Delayed Quote
USD
Rydex Biotechnology Inv (RYOIX)
96.80
+1.21
(+1.27%)
At close: 8:09:08 PM EST
Performance Overview
| Morningstar Return Rating | -- |
| YTD Return | 34.26% |
|---|---|
| 5y Average Return | 8.64% |
| Number of Years Up | 19 |
| Number of Years Down | 8 |
| Best 1Y Total Return (Nov 4, 2026) | 54.66% |
| Worst 1Y Total Return (Nov 4, 2026) | -- |
| Best 3Y Total Return | 54.66% |
| Worst 3Y Total Return | -2.90% |
Trailing Returns (%) Vs. Benchmarks
Monthly Total Returns
RYOIX
Category
- YTD
- 31.87%
- 7.95%
- 1-Month
- 4.00%
- 4.81%
- 3-Month
- 14.01%
- 7.18%
- 1-Year
- 39.61%
- 30.16%
- 3-Year
- 27.10%
- 16.10%
- 5-Year
- 8.84%
- 15.71%
- 10-Year
- 11.60%
- 15.27%
- Last Bull Market
- 37.89%
- 23.06%
- Last Bear Market
- -10.25%
- -13.88%
Annual Total Return (%) History
Year
RYOIX
Category
Past Quarterly Returns
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
|
2026
|
2.04% | 17.01% | 6.19% | -- |
|
2025
|
-1.35% | -0.13% | 15.14% | 15.24% |
|
2024
|
0.80% | 2.09% | 4.91% | -8.05% |
|
2023
|
-2.19% | 0.10% | -3.85% | 12.66% |
|
2022
|
-9.87% | -10.25% | -2.14% | 9.84% |
|
2021
|
-1.55% | 10.07% | -3.18% | -2.98% |
|
2020
|
-14.63% | 28.28% | 0.47% | 10.97% |
|
2019
|
18.46% | -3.65% | -8.49% | 19.69% |
|
2018
|
-0.10% | 3.93% | 7.81% | -18.69% |
|
2017
|
12.36% | 7.73% | 8.44% | -1.17% |
Rank in Category (By Total Return)
| YTD | 10 |
| 1-Month | 56 |
|---|---|
| 3-Month | 21 |
| 1-Year | 11 |
| 3-Year | 13 |
| 5-Year | 17 |
Load Adjusted Returns
| 1-Year | 39.61% |
| 3-Year | 27.10% |
|---|---|
| 5-Year | 8.84% |
| 10-Year | 11.60% |
Performance & Risk
| YTD Return | 34.26% |
| 5y Average Return | 8.64% |
| Rank in Category (ytd) | 10 |
| % Rank in Category (ytd) | -- |
| Beta (5Y Monthly) | 0.60 |
| Morningstar Risk Rating |
Fund Overview
| Category | Health |
| Fund Family | Rydex Funds |
| Net Assets | 161.17M |
| YTD Return | 31.87% |
| Yield | 0.00% |
| Morningstar Rating | |
| Inception Date | Sep 01, 2004 |
Fund Summary
Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.
